Overview
Mitochondrial dysfunction has been implicated in the pathogenesis of a plethora of neurodegenerative disorders (e.g., stroke, Parkinson's, amyotrophic lateral sclerosis, Huntington's, Alzheimer's, etc.). However, effective models useful for elucidating mechanisms and therapies associated with neuronal mitochondrial dysfunction are lacking. This invention describes a method that allows an in vivo, conditional, and cell- type specific expression of mitochondrially-targeted proteins.
Applications
Drug discovery
Validation studies
Research tool to identify the role of cell-type specific mitochondrial dysfunction
Advantages
-Provides a transgenic animal model that can be used to develop drugs that target specific neuronal mitochondrial populations.
-Provides a transgenic animal model that can be used to screen small molecules or compounds that promote neuronal mitochondrial protection
Stage of Development
A non-human transgenic animal model has been made that allows for the identification of mitochondria in a specific cell type
R&D Required
N/A
Licensing Potential
UM seeks to develop and commercialize by an exclusive or non-exclusive license agreement and/or sponsored research with a company active in the area
Contact Info
Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: [email protected]
Phone: (410) 706-2380